← Back to Search

Cell Therapy

Allogeneic HCT for Osteosarcoma (STIR Trial)

Phase 2

Waitlist Available

Led By Monica Thakar, MD

Research Sponsored by Monica Thakar

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

STIR Trial Summary

This trial is testing a new treatment for high-risk solid tumors that uses a patient's own cells. It is hoped that this treatment will be more effective than current treatments and have fewer side effects.

Eligible Conditions

Osteosarcoma
Brain Tumor
Rhabdomyosarcoma
Neuroblastoma
Ewing Sarcoma

STIR Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Disease-control rate

Secondary outcome measures

Overall survival

Other outcome measures

Non-relapse mortality

STIR Trial Design

1Treatment groups

Experimental Treatment

Group I: Allogeneic HCT + Donor NK Cell InfusionExperimental Treatment2 Interventions

Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Allogeneic HCT

2002

Completed Phase 3

~680

Donor NK Cell Infusion

2013

Completed Phase 2

~20

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Monica ThakarLead Sponsor

Monica Thakar, MDPrincipal InvestigatorMedical College of Wisconsin

1 Previous Clinical Trials

20 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research project accept new participants at the moment?

"This trial has concluded its search for participants. Initially posted on March 1st 2014, the study was last modified on April 5th 2022. For those looking to find alternative studies, 723 medical trials are currently seeking patients with neuroblastoma and 30 Allogeneic HCT clinical studies remain open to enrollment."

Answered by AI

Are there any precedent trials related to Allogeneic Hematopoietic Cell Transplantation?

"Currently, there are 30 research programs exploring Allogeneic HCT. None of these endeavors have reached Phase 3 yet, but 43 different medical facilities across the world - with a concentration in Wuxi, Jiangsu - are running trials for this particular treatment."

Answered by AI

Has Allogeneic HCT been affirmed by the FDA?

"The safety of allogeneic HCT is estimated to be a 2 since it has completed Phase 2 clinical trials, demonstrating some level of safety but no data proving efficacy."

Answered by AI

What is the total participant count for this clinical experiment?

"Unfortunately, this research is no longer enrolling participants. It was first posted on March 1st 2014 and its details were most recently revised on April 5th 2022. For other trials that may be of interest, there are currently 723 clinical studies recruiting patients with neuroblastoma and 30 for Allogeneic HCT."

Answered by AI

Recent research and studies

Expert Opinion on Emerging DrugsJournal

An Update on Emerging Drugs in Osteosarcoma: Towards Tailored Therapies?

Hattinger, Claudia Maria, Maria Pia Patrizio, Federica Magagnoli, Silvia Luppi, and Massimo Serra. 2019. “An Update on Emerging Drugs in Osteosarcoma: Towards Tailored Therapies?”. Expert Opinion on Emerging Drugs. Informa UK Limited. doi:10.1080/14728214.2019.1654455.

clinicaltrials.govStudy

Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors

Monica Thakar 2013. "Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02100891.